Marco Mascarella

Dr. Marco Mascarella


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2018 in Head & Neck
Verified
Journal Article
Closed access
PDF file
MMMarco Mascarella
Marco Mascarella
EMErin Mannard
Erin Mannard
SSSabrina Daniela Silva
Sabrina Daniela Silva
AZAnthony G. Zeitouni
Anthony G. Zeitouni

27 November 2019 in Head & Neck
Verified
Journal Article
Closed access
PDF file
NSNader Sadeghi
Nader Sadeghi
SKSarah Khalife
Sarah Khalife
MMMarco Mascarella
Marco Mascarella
ARAgnihotram V. Ramanakumar
Agnihotram V. Ramanakumar
KRKeith Richardson
Keith Richardson
RSRobert Siegel
Robert Siegel

25 March 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
NSNader Sadeghi
Nader Sadeghi
MMMarco Mascarella
Marco Mascarella
SKSarah Khalife
Sarah Khalife
ARAgnihotram V. Ramanakumar
Agnihotram V. Ramanakumar
KRKeith Richardson
Keith Richardson
RSRobert Siegel
Robert Siegel

22 June 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
JAJustine Georgina Albert
Justine Georgina Albert
CLChristopher Lo
Christopher Lo
ZRZeev Rosberger
Zeev Rosberger
Saul FrenkielSaul Frenkiel
Saul Frenkiel
MHMichael P. Hier
Michael P. Hier
Melissa HenryMelissa Henry
Melissa Henry
(1) Background: Patients and survivors of head and neck cancer (HNC) are at a high risk of developing body image concerns. Despite the prevalence of body image concerns in patients with HNC, there is a lack of longitudinal research exploring the wide array of its associated determinants. The current longitudinal study examined the determinants and longitudinal course of body image dissatisfaction in patients with HNC. (2) Methods: Patients participated in Structured Clinical Interviews and self-administered questionnaires at four time-points: (T1) upon cancer diagnosis, (T2) at 3 months post-diagnosis, (T3) at 6 months post-diagnosis, and (T4) at 12 months post-diagnosis. They also underwent a disfigurement rating on an objective scale. (3) Results: Two hundred and twenty-four patients participated in our study. Fourteen percent to twenty-eight percent of patients reported at least moderate body image concerns across time points, with the lowest rates at baseline and the highest at 3 months (T1). It was found that patients more predisposed to developing higher levels of body image concerns presented physical markers (i.e., advanced cancer stage, lower physical functioning, higher disfigurement), psychosocial markers (i.e., higher depression, higher anxiety, and higher levels of coping with denial), and health disparities (i.e., younger age, female sex, French language, and marital status, with divorced and widowers most affected). (4) Conclusions: The findings of this study highlight the multifaceted nature of body image concerns in patients with HNC and its biopsychosocial determinants. Clinicians should pay specific attention to these biopsychosocial markers in their clinics to predict high levels of body image concerns and tailor communication/refer for support accordingly.

3 January 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Purpose: Neoadjuvant targeted therapy provides a brief, preoperative window of opportunity that can be exploited to individualize cancer care based on treatment response. We investigated whether response to neoadjuvant therapy during the preoperative window confers survival benefit in patients with operable head and neck squamous cell carcinoma (HNSCC). Patients and Methods: A pooled analysis of treatment-naïve patients with operable HNSCC enrolled in one of three clinical trials from 2009 to 2020 (NCT00779389, NCT01218048, NCT02473731). Neoadjuvant regimens consisted of EGFR inhibitors (n = 83) or anti-ErbB3 antibody therapy (n = 9) within 28 days of surgery. Clinical to pathologic stage migration was compared with disease-free survival (DFS) and overall survival (OS) while adjusting for confounding factors using multivariable Cox regression. Circulating tumor markers validated in other solid tumor models were analyzed. Results: 92 of 118 patients were analyzed; all patients underwent surgery following neoadjuvant therapy. Clinical to pathologic downstaging was more frequent in patients undergoing neoadjuvant targeted therapy compared with control cohort (P = 0.048). Patients with pathologic downstage migration had the highest OS [89.5%; 95% confidence interval (CI), 75.7–100] compared with those with no stage change (58%; 95% CI, 46.2–69.8) or upstage (40%; 95% CI, 9.6–70.4; P = 0.003). Downstage migration remained a positive prognostic factor for OS (HR, 0.22; 95% CI, 0.05–0.90) while adjusting for measured confounders. Downstage migration correlated with decreased circulating tumor markers, SOX17 and TAC1 (P = 0.0078). Conclusions: Brief neoadjuvant therapy achieved pathologic downstaging in a subset of patients and was associated with significantly better DFS and OS as well as decreased circulating methylated SOX17 and TAC1.

20 August 2021 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Open access
PDF file
MMMarco Mascarella
Marco Mascarella
NMNikesh Muthukrishnan
Nikesh Muthukrishnan
FMFarhad Maleki
Farhad Maleki
MKMarie-Jeanne Kergoat
Marie-Jeanne Kergoat
KRKeith Richardson
Keith Richardson
RFReza Forghani
Reza Forghani
Objective: Major postoperative adverse events (MPAEs) following head and neck surgery are not infrequent and lead to significant morbidity. The objective of this study was to ascertain which factors are most predictive of MPAEs in patients undergoing head and neck surgery. Methods: A cohort study was carried out based on data from patients registered in the National Surgical Quality Improvement Program (NSQIP) from 2006 to 2018. All patients undergoing non-ambulatory head and neck surgery based on Current Procedural Terminology codes were included. Perioperative factors were evaluated to predict MPAEs within 30-days of surgery. Age was classified as both a continuous and categorical variable. Retained factors were classified by attributable fraction and C-statistic. Multivariate regression and supervised machine learning models were used to quantify the contribution of age as a predictor of MPAEs. Results: A total of 43 701 operations were analyzed with 5106 (11.7%) MPAEs. The results of supervised machine learning indicated that prolonged surgeries, anemia, free tissue transfer, weight loss, wound classification, hypoalbuminemia, wound infection, tracheotomy (concurrent with index head and neck surgery), American Society of Anesthesia (ASA) class, and sex as most predictive of MPAEs. On multivariate regression, ASA class (21.3%), hypertension on medication (15.8%), prolonged operative time (15.3%), sex (13.1%), preoperative anemia (12.8%), and free tissue transfer (9%) had the largest attributable fractions associated with MPAEs. Age was independently associated with MPAEs with an attributable fraction ranging from 0.6% to 4.3% with poor predictive ability (C-statistic 0.60). Conclusion: Surgical, comorbid, and frailty-related factors were most predictive of short-term MPAEs following head and neck surgery. Age alone contributed a small attributable fraction and poor prediction of MPAEs. Level of evidence: 3